Priority Of Merck's Integration Of Schering Is Retaining Top R&D Talent - Kim
Executive Summary
Merck's acquisition of Schering-Plough won't close until the fourth quarter, but the drug maker is already wading through a pipeline review to determine which research programs will get a green light as part of the combined company and which ones might get shelved
You may also be interested in...
Get Attitude, Drive Cultural Transformation, Fred Hassan Tells Execs At TAP
Cultural transformation was the main topic of Warburg Pincus managing director Fred Hassan’s keynote talk at the Therapeutic Area Partnerships meeting on Nov. 19, where the audience also drew on the investor’s extensive track record leading some of pharma’s most successful turnarounds.
FTC Approves the Pfizer-Wyeth Deal And Keeps Their Human Drug Portfolio Intact
The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.
Schering Telescope Points To 5 R&D “Stars,” But TRA Shines Brightest
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on